daratumumab
E852348
Daratumumab is a monoclonal antibody drug used primarily to treat multiple myeloma by targeting and destroying malignant plasma cells.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| Daratumumab | 1 |
Statements (59)
| Predicate | Object |
|---|---|
| instanceOf |
CD38-targeting antibody
ⓘ
antineoplastic agent ⓘ immunotherapy drug ⓘ monoclonal antibody ⓘ |
| antibodyType | IgG1 kappa ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L01FD02 ⓘ |
| bindsTo | CD38 antigen on plasma cells NERFINISHED ⓘ |
| canInterfereWith |
blood compatibility testing
ⓘ
indirect antiglobulin test ⓘ |
| coDevelopedBy | Janssen Biotech NERFINISHED ⓘ |
| commonAdverseEffect |
anemia
ⓘ
infusion-related reaction ⓘ neutropenia ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| developedBy | Genmab NERFINISHED ⓘ |
| eliminationHalfLife | approximately 18 days ⓘ |
| EMAAuthorizationYear | 2016 ⓘ |
| FDAApprovalYear | 2015 ⓘ |
| hasBrandName |
Darzalex
NERFINISHED
ⓘ
Darzalex Faspro NERFINISHED ⓘ |
| indicatedFor |
light chain (AL) amyloidosis
NERFINISHED
ⓘ
newly diagnosed multiple myeloma in transplant-eligible patients ⓘ newly diagnosed multiple myeloma in transplant-ineligible patients ⓘ refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| isHuman | true ⓘ |
| legalStatus | prescription-only medicine ⓘ |
| mechanismOfAction |
induces antibody-dependent cell-mediated cytotoxicity
ⓘ
induces antibody-dependent cellular phagocytosis ⓘ induces apoptosis via cross-linking ⓘ induces complement-dependent cytotoxicity ⓘ modulates immune suppressor cells in the tumor microenvironment ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| requiresPremedication |
antihistamines
ⓘ
antipyretics ⓘ corticosteroids ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targetCellType |
malignant plasma cell
ⓘ
normal plasma cell ⓘ |
| targets | CD38 NERFINISHED ⓘ |
| usedFor | multiple myeloma ⓘ |
| usedInCombinationWith |
bortezomib
NERFINISHED
ⓘ
bortezomib and dexamethasone ⓘ bortezomib and melphalan and prednisone ⓘ carfilzomib ⓘ carfilzomib and dexamethasone ⓘ cyclophosphamide ⓘ cyclophosphamide and bortezomib and dexamethasone ⓘ dexamethasone NERFINISHED ⓘ lenalidomide ⓘ lenalidomide and dexamethasone ⓘ melphalan ⓘ pomalidomide ⓘ pomalidomide and dexamethasone ⓘ thalidomide ⓘ |
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.